In a breaking announcement, the European Court of Justice has deemed that CBD isn't a narcotic under EU law.
The European CBD market may very well get a boost this morning, following news that The European Court of Justice (ECJ) determined CBD, Cannabidiol, isn't a narcotic.
What this means, in essence, is that CBD isn't considered to have any harmful effects upon humans or any psychotropic effects.
As many will know, CBD is the non-psychoactive compound within the cannabis plant, which provides many of the same health benefits as THC, without the capacity for users to get high.
The ECJ's recent ruling on CBD came in response to a court case in which a company, KanaVape, faced prosecution for importing CBD vaporizer cartridges in France. Amid this, the ECJ ruled that CBD is not a narcotic.
The ECJ stated that banning CBD is "contrary to the general spirit of that convention and to its objective of protecting 'the health and welfare of mankind," while also stating that:
"A decision to prohibit the marketing of CBD, which indeed constitutes the most restrictive obstacle to trade in products lawfully manufactured and marketed in other [EU] member states, can be adopted only if that risk appears sufficiently established."
The ruling is hugely impactful for CBD policy moving forward throughout Europe, as it also means that all EU nations will have to allow for the marketing of CBD and CBD-related products.
The court ruling follows a recent decision by Italy to deem CBD a narcotic after the compound was placed on the country's list of medicines.
The European CBD Market is predicted to be worth roughly €450 million currently, representing the second-largest CBD market next to North America. The European CBD market is projected to be worth at least €1.5 billion by 2023.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors